CityUHK researchers advance spatial omics to routine clinical use
HONG KONG, Sept. 28, 2026 /PRNewswire/ -- Recently, spatial omics has become a powerful tool, enabling researchers to see not only what molecules are present in a tissue, but also where they are located and how they are organised across cells, tissue structures and local microenvironments. This spatial context has significantly deepened our understanding of cancer, neurobiology and...
111, Inc. Announces Establishment of the Special Committee
SHANGHAI, Sept. 28, 2026 /PRNewswire/ -- 111, Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, announced today that the special committee (the "Special Committee"), comprising of three independent directors, Mr. Jian Sun, who is the chairman of the Special Committee, Mr. Nee Chuan Teo and Mr. Jun Luo, has been...
SOLA Biosciences Japan Receives AMED Grant to Advance SOL-257, Innovative Gene Therapy Aiming to Restore TDP-43 Function for ALS Patients
TOKYO and BOSTON, Sept. 28, 2026 /PRNewswire/ -- SOLA Biosciences Japan GK ("SOLA Japan"), the wholly owned Japanese subsidiary of Boston-based SOLA Biosciences Inc. (together, "SOLA"), announced that it has been awarded a grant of approximately 6 billion yen over five years by the Japan Agency for Medical Research and Development ("AMED") under the Strengthening Program for Pharmaceutical...
Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer
HONG KONG, Sept. 28, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicenter Phase III head-to-head trial evaluating cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, in combination with chemotherapy versus chemotherapy with or without nivolumab as first-line treatment for patients with HER2-negative, previously...
Metaverse Lab-XR: Virtual Lab Builds Diagnostic and Teamwork Skills for Medical Technology Students
A Chula Medical Technology lecturer has developed Metaverse Lab-XR, an innovative virtual laboratory that allows students to practice lab procedures and develop the soft skills needed for real-world work in hospitals, preparing them to become skilled and knowledgeable medical technologists. BANGKOK, Sept. 28, 2026 /PRNewswire/ -- For Medical Technology students, laboratory skills are just as important as academic learning....
Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC
SAN FRANCISCO and SUZHOU, China, Sept. 28, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, metabolic, and ophthalmic diseases, announces expansion of the global Phase 3 MarsLight-11 (NCT07217301) trial, which is evaluating IBI363 (Takeda R&D code: TAK-928) in patients...
2026 IMS | IASO Bio Presented FUCASO China Real-World Data
--- In a large China real-world study of 281 heavily pretreated, predominantly high-risk patients with relapsed/refractory plasma cell neoplasms, FUCASO achieved a 95.9% objective response rate, a 77.2% CR/sCR rate, and a 94.1% MRD negativity rate --- with median PFS and OS not yet reached (12-month PFS 71.5%, OS 87.8%) and consistent benefit across high-risk subgroups, validating...
2026 IMS | IASO Bio Presented First-in-Human Data of BCMA-Targeted In Vivo CAR-T Cell Therapy IASO206
— Late-breaking oral presentation of first-in-human data (LBA-11) showed that a single intravenous infusion of IASO206 generated functional BCMA CAR-T cells in vivo without lymphodepleting chemotherapy. The study demonstrated a 90% objective response rate and a 90% MRD negativity rate in a population in which 90% of patients had high-risk and 70% had ultra-high-risk cytogenetic features; both rates...
Second NRF2 Degrader Enters Clinical Development: Nutshell Therapeutics’ NTS231 Received FDA IND Clearance
SHANGHAI, Sept. 25, 2026 /PRNewswire/ -- Nutshell Therapeutics (Shanghai) Co., Ltd. ("Nutshell Therapeutics"), an innovative biotech company focused on AI-driven allosteric drug discovery, announced FDA IND clearance for NTS231, a covalent allosteric molecular glue degrader of NRF2, to launch clinical development in the United States. NTS231 is the first NRF2 degrader molecule from China and second globally to...
Lundbeck to establish global innovation hub in Greater Boston and relocate US headquarters
The new hub in Greater Boston will bring Lundbeck closer to one of the world's leading life sciences ecosystems, strengthening access to science, talent and partnerships. The move is part of Lundbeck's continued investment in the US, a key market, and will support the company's Focused Innovator strategy and long-term growth. The transition from Deerfield will take...
